Vimarsana
Biggest News Aggregation in the World

Page 2 - Breakthrough Device News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Device. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Device Today - Breaking & Trending Today

CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US - Vimarsana News

CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US

(This story has not been edited by THE WEEK and is auto-generated from a PTI

Source: theweek.in
CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US - Vimarsana News

CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US

/PRNewswire/ -- Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its groundbreaking IDE clinical...

CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US - Vimarsana News

CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US

TAMPA, Fla., April 20, 2024 /PRNewswire/ -- Concept Medical, a pioneer in innovative drug delivery technologies, proudly announces the commencement of its

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368 - Vimarsana News

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368

ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in...

Acrivon Therapeutics Announces $130 Million Private Placement Financing - Vimarsana News

Acrivon Therapeutics Announces $130 Million Private Placement Financing

WATERTOWN, Mass, April 09, 2024 -- Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are...